GSK Invests $10.6 Billion in Lung Cancer Research and Development

Pharmaceutical giant GSK has committed $10.6 billion to a significant investment in lung cancer research and development, signaling a major strategic bet in the oncology sector.

9 Jun, 16:57 — 9 Jun, 16:57

Post Share

Sources

Showing 1 of 2 sources

FTVery High60d ago

GSK’s $10.6bn cancer deal will lead to more

Making additional moves would be in keeping with pharma group’s strategy of building its pipeline as fast as possible

Read full article →

Coverage Timeline

First report: Yahoo · 9 Jun, 15:29|Full coverage: 2 · 1h|Window: 1h

Left-leaningCenterRight-leaning

Yahoo9 Jun, 15:29First to report

GSK Just Dropped $10.6 Billion on a Lung Cancer Bet

1h later

FT9 Jun, 16:57Latest update

PERSPECTA

PERSPECTA

GSK Invests $10.6 Billion in Lung Cancer Research and Development

Sources

GSK’s $10.6bn cancer deal will lead to more

Coverage Timeline

GSK Just Dropped $10.6 Billion on a Lung Cancer Bet

GSK’s $10.6bn cancer deal will lead to more

Related Stories

MTN Nigeria Confirms 25GB Data Reward, Warns Against Fake Links

Erdinger Owner Werner Brombach Dies

West Bengal to Audit Industrial Parks, Submit BHAVYA Proposals

Climate Change Threatens Nigerian Coastal Fishermen's Livelihoods

PERSPECTA